Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

Exclusion Criteria

• •1. Known transformation to aggressive lymphoma, eg, large cell lymphoma
• •2. Clinically significant cardiovascular disease
• •3. Prior malignancy within the past 2 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score 6 prostate cancer
• •4. History of severe bleeding disorder such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or other medical intervention
• •5. History of stroke or intracranial hemorrhage
• •6. Severe or debilitating pulmonary disease
• •7. Active fungal, bacterial and/or viral infection requiring systemic therapy
• •8. Known central nervous system involvement by lymphoma
• •9. Known infection with HIV, or serologic status reflecting active viral hepatitis B (HBV) or viral hepatitis C (HCV) infection
• •10. Major surgery within 4 weeks of the first dose of study drug
• •11. Prior treatment with a Bruton's tyrosine kinase (BTK) inhibitor
• •12. Pregnant or lactating women
• •13. Requires ongoing treatment with a strong Cytochrome P4503A (CYP3A) inhibitor or inducer
• •14. Concurrent participation in another therapeutic clinical trial